Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas
ALLSCHWIL, Switzerland, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced results from an in vitro study evaluating the effects of combining Spexis’ potent CXCR4 inhibitor balixafortide (BLX) with several conventional or targeted therapies on the market in B-cell lymphoma models. The research was conducted under the leadership of Prof. Francesco Bertoni at the renowned Institute of Oncology Research in Bellinzona, Switzerland.
ALLSCHWIL, Switzerland, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the results of a Phase 1 clinical trial with balixafortide (“BLX”), a potent, specific and highly selective macrocycle inhibitor of CXCR4. This study was undertaken to investigate whether dosing of BLX needs to be adjusted in patients with renal impairment as part of any future market approval submission.
EQS-Adhoc: Polyphor provides update on the future of the FORTRESS study of
ALLSCHWIL, Switzerland, June 28, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN), a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance today announced that its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did not meet its co-primary endpoint.
Swiss biotech Polyphor has seen its key cancer asset balixafortide fail a late-stage trial, leaving its future in the balance.
ALLSCHWIL, Switzerland, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) announced today that the clinical trial independent Data Safety Monitoring Board (DSMB) has completed the third, pre-specified interim analysis, of safety outcomes based on a data cut off of 401 randomized patients in the Phase III pivotal study with balixafortide in HER2 negative, locally recurrent or metastatic breast cancer patients. The DSMB indicated that the Phase III clinical study should continue without modifications.
Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer